Patents by Inventor Josef Michl

Josef Michl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210205403
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: March 5, 2021
    Publication date: July 8, 2021
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20210171704
    Abstract: Methods of forming a porphene polymeric material are provided. The resulting material can be a porphene or a metalloporphene polymeric material. The structure of the polymer can be selected based on a material provided in the monomer material. Methods of using the polymeric material are also provided.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 10, 2021
    Applicant: The Regents of the University of Colorado, A Body Corporate
    Inventors: Josef Michl, Thomas Frank Magnera
  • Publication number: 20200038471
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 6, 2020
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20200002394
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 2, 2020
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20170209521
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 27, 2017
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20170065684
    Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
    Type: Application
    Filed: July 27, 2015
    Publication date: March 9, 2017
    Inventors: Matthew Pincus, Josef Michl
  • Publication number: 20170022288
    Abstract: The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 26, 2017
    Inventors: Josef Michl, Stefan M. Bradu, Raquib Hannan, Matthew R. Pincus
  • Patent number: 9539327
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 10, 2017
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20160083475
    Abstract: The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 24, 2016
    Inventors: Josef Michl, Stefan M. Bradu, Raquib Hannan, Matthew R. Pincus
  • Publication number: 20150320841
    Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Inventors: Matthew Pincus, Josef Michl
  • Patent number: 9115213
    Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: August 25, 2015
    Assignee: The Research Foundation of State University of New York
    Inventors: Matthew Pincus, Josef Michl
  • Publication number: 20140371156
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 18, 2014
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Patent number: 8822419
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 2, 2014
    Assignee: The Research Foundation of State University of New York
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Publication number: 20130065953
    Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 14, 2013
    Inventors: Matthew Pincus, Josef Michl
  • Publication number: 20120177566
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: October 2, 2009
    Publication date: July 12, 2012
    Inventors: Matthew R. Pincus, Josef Michl
  • Publication number: 20110183915
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 28, 2011
    Inventors: Matthew R. Pincus, Josef Michl
  • Patent number: 7883888
    Abstract: The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane penetrating leader sequence are also provided. The present invention also provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence operably linked to a nucleotide sequence encoding a subject peptide. Methods of selectively killing cancer cells in a subject by administering a therapeutically effective amount of a subject AdV vector are also provided by the present invention.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: February 8, 2011
    Assignee: The Research Foundation —The State University of New York
    Inventors: Josef Michl, Jesko Koehnke, Matthew R. Pincus
  • Patent number: 7737234
    Abstract: Provided is a method for polymerizing a polymer precursor, comprising: contacting a polymer precursor with a lithium carborane catalyst and an initiator under polymerizing conditions. A reaction solvent may be used, but is not necessary. Also provided is a method of preparing lithium carborane polymers, comprising: contacting a lithium carborane polymer precursor having a terminal alkenyl or alkynyl group with an initiator and an optional reaction solvent under polymerizing conditions. Functionalized carborane anions are also provided.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: June 15, 2010
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Josef Michl, Kamesh Vyakaranam, Stefanie Koerbe
  • Publication number: 20100144636
    Abstract: A method of treating ras-transformed and ras-related cancer, including: administering to a plurality cells, including ras-transformed cancer cells and normal cells, a peptide material having a membrane resident peptide and a ras-p21 component, the membrane resident peptide attached to the carboxyl or amino terminal end of the ras-p21 component.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 10, 2010
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Victor Adler
  • Publication number: 20090286861
    Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 19, 2009
    Applicant: The Research Foundation of State University of New York
    Inventors: Matthew Pincus, Josef Michl